Aignosis
AI-assisted, webcam-based screening platform for autism and developmental risks in children aged 16 months to nine years.
Website: https://aignosis.in/
Cover Block
From the public record
| Field | Value |
|---|---|
| Company | Aignosis |
| Tagline | AI-assisted, webcam-based screening platform for autism and developmental risks in children aged 16 months to nine years [Seedtable] |
| Headquarters | Jaipur, India [Business Outreach, October 2026] |
| Founded | 2024 [Business Outreach, October 2026] |
| Stage | Seed [Economic Times Entrepreneur, October 2026] |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | South Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2), Raksheet Jain and Divyansh Mangal [VCCircle, October 2026] |
| Funding Label | Seed |
| Total Disclosed | Approximately $450,000 [Economic Times Entrepreneur, October 2026] |
Links
From the public record
- Website: https://aignosis.in/
The Short Version
PUBLIC Aignosis is a Jaipur-based healthtech startup building an AI-assisted, webcam-based screening platform for autism and related developmental risks in children, and it merits attention now because it has paired an unusually low-hardware product design with early public-sector and school deployment in India at seed stage [Economic Times Entrepreneur, October 2026] [VCCircle, October 2026] [MediaNama, October 2026]. Founded in 2024 by Raksheet Jain and Divyansh Mangal, the company is still early, but the public record shows a coherent wedge: put a screening workflow into existing pediatric and care settings rather than ask families or providers to adopt specialized equipment [Economic Times Entrepreneur, October 2026] [VCCircle, October 2026].
The product uses computer vision through a standard laptop webcam to analyze behavioral signals such as eye gaze, response to name, and reactions to facial expressions, then generates a risk report; public coverage consistently frames it as a screening tool, not a diagnostic system, which matters both clinically and commercially [VCCircle, October 2026] [MediaNama, October 2026]. That hardware-light approach appears to be the main point of differentiation in the materials reviewed, alongside reported deployment across more than 20 government primary health centres in Rajasthan and expansion to 125 schools [Indian Startup News, October 2026] [MediaNama, October 2026].
On team, the available evidence points to technically oriented founders rather than repeat healthcare operators: LinkedIn and profile materials tie Jain to an artificial intelligence background at NMIMS, while Mangal is described as having a physics background from BITS Pilani and work spanning AI and quantum technology [LinkedIn, Retrieved 2026] [F6S] [LinkedIn, Retrieved 2026]. That is directionally consistent with the product's machine-vision emphasis, though the public record is thinner on prior scaled healthcare distribution experience.
Capitalization is straightforward in public sources. Aignosis disclosed a seed round of about $450,000 in October 2026, led by Antler, with participation reported from Nikhil Kamath, Varun Dua, IIMA Ventures, Aman Gupta, Peyush Bansal, Amit Jain, and GirnarSoft Ventures; the company is categorized here as B2B2C, which fits its provider- and institution-led deployment model [Economic Times Entrepreneur, October 2026] [FinSMEs, October 2026].
For the next 12 to 18 months, the central questions are execution and evidence quality rather than category demand. Publicly cited traction has reached more than 8,000 screenings, with a stated target of at least 100,000 by the end of FY2026-27, but MediaNama also noted the absence of publicly available error-rate data, so investors should watch whether screening volume scales alongside validation, channel durability, and conversion from pilots into repeatable institutional adoption [Gate, October 2026] [Dealroom News, October 2026] [MediaNama, October 2026].
Single-source, plausible -- Relies on named public reporting and LinkedIn corroboration, but several material claims remain single-source or company-adjacent, including founder background detail and performance evidence.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | South Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed about $450,000 [Economic Times Entrepreneur, October 2026] |
The Company in Brief
PUBLIC
Aignosis presents a fairly recent company formation with a narrow initial use case, which matters because the public record is still thin and most of what can be stated with confidence is basic corporate identity and product scope. The company is based in Jaipur, India, was founded in 2024, and describes itself as an AI-assisted, webcam-based screening platform focused on autism and developmental risk screening for children aged 16 months to nine years [aignosis.in] [Seedtable].
The founding team publicly listed in available sources consists of Raksheet Jain and Divyansh Mangal [Seedtable] [linkedin.com]. Their names recur across company and profile materials, but the public record does not surface a legal entity filing in the materials reviewed here, so the overview is best read as an operating snapshot rather than a full corporate registry check [aignosis.in] [linkedin.com].
From a milestone standpoint, the chronology is short but clear enough. Aignosis was founded in 2024, then by October 2026 had entered the market more visibly through its disclosed seed financing and public rollout across government health centres and schools, indicating movement from early product build into initial distribution partnerships and field deployment [Seedtable] [aignosis.in].
Single-source, plausible -- Confirmed in part by company website and Seedtable; founder identity is partially corroborated by LinkedIn, but no state filing was available in the reviewed public materials.
What They Have Built
MIXED
What is visible in the public record is a narrowly scoped screening product, not a general pediatric AI platform. Aignosis describes an AI-assisted, webcam-based system for screening autism and other developmental risks in children aged 16 months to nine years, using a standard laptop webcam rather than specialized hardware [Seedtable] [VCCircle, October 2026]. Press coverage says the software analyzes behavioral signals such as eye gaze, response to name, and reactions to facial expressions, then generates a risk report for possible developmental concerns [VCCircle, October 2026]. One outlet adds that the workflow spans nine stimulus modules, which helps clarify that this is a structured assessment flow rather than passive video capture alone [IPO Platform].
The practical point is accessibility. Multiple reports frame the product as non-invasive and built to run on ordinary camera-equipped laptops, which, if sustained in real-world settings, lowers deployment friction for clinics and schools relative to hardware-heavy screening setups [Aignosis] [Bharat Speaks] [Inc42, October 2026]. The same sources are careful, or should be, on scope: MediaNama describes Aignosis as a screening tool rather than a diagnostic system, a distinction that matters in pediatric care because screening flags risk and does not establish a clinical diagnosis [MediaNama, October 2026] [Ezra].
There is also an early regulatory and evidence signal, but it is still incomplete in public. Gate reported that Aignosis received CDSCO Class B certification for its laptop-and-webcam tool, which, if independently corroborated, would be a meaningful credibility marker for an Indian healthtech product entering clinical workflows [Gate, October 2026]. At the same time, MediaNama reported that publicly available materials did not disclose error-rate data for the screening system, leaving a central diligence question unanswered: how sensitivity, specificity, and false-positive rates perform across age bands and settings [MediaNama, October 2026]. That gap does not invalidate the wedge, but it does limit how far a public-market reader can go in assessing technical defensibility versus distribution execution.
Single-source, plausible -- Product scope is corroborated by multiple public sources including VCCircle, MediaNama, and Seedtable, but regulatory certification and performance transparency remain only partially corroborated in the cited public record.
Market Size and Demand
PUBLIC
The market matters now because Aignosis sits at the intersection of pediatric developmental screening, low-cost computer-vision software, and a public-health push for earlier identification, a combination that tends to widen distribution faster than clinical diagnostics alone [MediaNama, October 2026] [VCCircle, October 2026].
The evidence base here is narrower than an institutional investor would usually want for formal TAM work. No named third-party market report in the supplied research quantifies autism screening, pediatric developmental screening, or webcam-based behavioral assessment in India, so any market sizing would be directional rather than investment-grade. What is public, and more useful at this stage, is the shape of the wedge: Aignosis is described as a screening tool rather than a diagnostic system, aimed at children aged 16 months to nine years, and designed to run on a standard laptop webcam rather than specialized equipment [MediaNama, October 2026] [Seedtable] [VCCircle, October 2026]. That positioning suggests its practical addressable market is broader than specialist autism clinics. It potentially reaches government primary health centres, schools, pediatric practices, and outreach camps, provided those channels can absorb a screening workflow and a referral path for follow-up assessment [Economic Times Entrepreneur, October 2026] [MediaNama, October 2026] [VCCircle, October 2026].
Demand signals in the public record are early but real. More than 20 government primary health centres in Rajasthan had deployed the system by October 2026, according to multiple reports, and MediaNama separately reported expansion to 125 schools [Economic Times Entrepreneur, October 2026] [Indian Startup News, October 2026] [MediaNama, October 2026]. Reported screenings had exceeded 8,000 by the same period, with management targeting at least 100,000 by the end of FY2026-27, a large jump that should be treated as a company goal rather than observed run rate [Gate, October 2026] [Dealroom News, October 2026] [Indian Retailer, October 2026]. The stronger point is not the target itself. It is that public-sector clinics and school settings appear willing to test a lighter-weight screening format if the hardware burden is low and the workflow does not require hospital-grade infrastructure [Gate, October 2026] [IPO Platform].
The adjacent markets are easier to identify than to size with the material provided. One is conventional pediatric developmental assessment, where screening tools feed referrals into clinical diagnosis and therapy. Another is school-based child wellness and special-needs identification, where the buyer logic is less about diagnosis and more about early flagging and parent referral [MediaNama, October 2026]. A third is broader digital health infrastructure for primary care, particularly software that can extend specialist-like triage into under-served settings. Aignosis's clinic-in-clinic model, as described by VCCircle, also places it near substitute pathways such as pediatric observation during routine visits, paper-based developmental checklists, and in-person specialist assessment, all of which compete less on algorithmic sophistication than on trust, cost, and ease of use [VCCircle, October 2026].
Regulation is a meaningful variable in this category. Gate reported that Aignosis received CDSCO Class B certification for its laptop-and-webcam tool, which, if sustained, can help with procurement credibility and health-system adoption, though it does not answer the separate question of clinical accuracy in real-world use [Gate, October 2026]. That distinction matters because MediaNama noted the absence of public error-rate data, and screening products in pediatric behavioral health are unusually sensitive to false positives, false negatives, and follow-up capacity constraints [MediaNama, October 2026]. In plain terms, the macro tailwind is clear: health systems want earlier, cheaper screening. The gating factor is whether evidence generation keeps pace with distribution.
| Public market signal | Figure | Context |
|---|---|---|
| Government primary health centres deployed | 20+ | Rajasthan deployment footprint reported in October 2026 [Economic Times Entrepreneur, October 2026] |
| Schools reached | 125 | Expansion reported by MediaNama in October 2026 [MediaNama, October 2026] |
| Screenings completed | 8,000+ | Reported cumulative screenings by October 2026 [Gate, October 2026] |
| Screening target | 100,000 | Company target by end of FY2026-27 [Gate, October 2026] |
The table does not size the market, but it does show where early demand is surfacing: public clinics, schools, and screening-volume ambitions rather than specialist-center sales. For investors, that points to a distribution-led market build, with the category's eventual size likely determined by validation, reimbursement logic, and referral conversion rather than raw need alone.
Single-source, plausible -- Section rests on credible publisher reporting for deployments, product scope, and regulatory status, but no named third-party market-sizing report was available in the supplied research, and key market claims remain directional rather than independently quantified.
Who Else Is Fighting for This
Competitive map
MIXED Aignosis is not competing head-on with a crowded list of named autism-screening startups in the sourced record, it is competing against a mix of incumbent clinical pathways, school-led observation, and adjacent pediatric assessment workflows that already sit closer to the child than a new software tool does [MediaNama, October 2026] [VCCircle, October 2026].
The first competitive layer is the incumbent care pathway. Aignosis describes its product as a screening system, not a diagnostic one, which places it upstream of formal clinical diagnosis and closer to triage, referral, and early flagging in pediatric and community settings [MediaNama, October 2026] [VCCircle, October 2026]. In practice, that means its alternatives are less likely to be a one-for-one software rival and more likely to be pediatric observation, caregiver questionnaires, specialist referral queues, and school-based identification processes. The appeal of Aignosis in that context is operational: it uses a standard laptop webcam and computer vision to generate a risk report, which could fit sites that lack specialist capacity or medical hardware budgets [VCCircle, October 2026] [IPO Platform].
The second layer is adjacent institutional channels. Aignosis has been reported in more than 20 government primary health centres in Rajasthan, and MediaNama reported expansion from those centres to 125 schools, which suggests the company is trying to occupy two distribution surfaces at once: public-health screening and school-linked child monitoring [Economic Times Entrepreneur, October 2026] [Indian Startup News, October 2026] [MediaNama, October 2026]. That positioning matters because a school or primary-care workflow can become sticky even if the underlying model is not singular. The channel, not only the algorithm, may determine adoption. By contrast, any future rival with stronger hospital relationships, deeper pediatric brand recognition, or embedded school-service contracts could bypass the product comparison and win at procurement.
Aignosis does have a visible edge today, but it is narrower than seed-round coverage can make it appear. The strongest public signals are distribution and basic regulatory progress: deployment in Rajasthan government centres, reported expansion to 125 schools, and a reported CDSCO Class B certification for the laptop-and-webcam tool [Economic Times Entrepreneur, October 2026] [MediaNama, October 2026] [Gate, October 2026]. Those are useful barriers for a young company because they imply some combination of field usability, administrative buy-in, and compliance work. Still, the durability of that edge is mixed. Distribution can deepen if these pilots convert into recurring institutional programs, but the technical edge looks more perishable because the public record does not show disclosed error-rate data, proprietary dataset detail, or peer-reviewed performance benchmarks that would be hard for a better-capitalized entrant to replicate [MediaNama, October 2026].
The company is most exposed where trust and validation matter more than accessibility. MediaNama specifically noted that public materials did not provide error-rate data for the screening system, and that absence is a real competitive vulnerability in a clinical-adjacent category where pediatricians, schools, governments, and parents may ask for sensitivity, specificity, and false-positive trade-offs before scaling usage [MediaNama, October 2026]. Aignosis is also exposed to adjacent incumbents that already own the decision point, even if they are not named as direct software rivals in the source set. A pediatric network, hospital foundation, or established developmental-assessment provider with stronger clinical evidence could be the winner if procurement shifts from access and affordability toward published validation. Aignosis would be the loser if its current channel presence does not translate into evidence that convinces referral-setting clinicians.
The most plausible 18-month scenario is a split market rather than a single winner. Aignosis is well placed if the category is won by low-cost, field-deployable screening tied to schools and primary care, because its webcam-based setup and early public-sector footprint are aligned with that use case [VCCircle, October 2026] [Economic Times Entrepreneur, October 2026]. The likely winner if that condition holds is Aignosis itself. The likely loser if the category instead consolidates around formal clinical validation and specialist-led adoption is any screening-first model without publicly demonstrated performance thresholds, and on current evidence Aignosis fits that risk more than it escapes it [MediaNama, October 2026].
Opportunity
PUBLIC
The prize here is unusually large for a young healthtech company because a low-cost, webcam-based screener that fits inside ordinary pediatric and school workflows could become one of the default intake layers for developmental-risk detection across India’s fragmented child-health system, if the current deployment and distribution signals continue to hold [Economic Times Entrepreneur, October 2026] [VCCircle, October 2026] [MediaNama, October 2026].
The headline opportunity is not to replace clinicians. It is to become the standard first-pass screening infrastructure that sits upstream of diagnosis, referral, and follow-up for childhood developmental concerns. That is a narrower claim, but a more credible one on the public record: Aignosis is described as a screening tool rather than a diagnostic system, it runs on a standard laptop webcam, and it has already moved beyond pilot language into real deployments across more than 20 government primary health centres in Rajasthan, with MediaNama reporting expansion to 125 schools [MediaNama, October 2026] [VCCircle, October 2026] [Economic Times Entrepreneur, October 2026]. For an early company founded in 2024, that matters. The combination of ordinary hardware, institutional settings, and a B2B2C motion gives it a plausible route to scale that does not depend on selling an expensive medical device one clinic at a time [Seedtable] [VCCircle, October 2026].
The upside paths are still conditional, but they are visible enough to map. The table below frames three distinct ways the company could compound from an early screening product into a larger platform outcome.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Public-health screening layer | Aignosis becomes a standard screening workflow across state health systems and affiliated primary-care settings, with the product used as an early triage layer before specialist referral | More state-level deployments after the Rajasthan health-centre footprint, supported by its reported CDSCO Class B certification and seed financing for India expansion [Gate, October 2026] [Economic Times Entrepreneur, October 2026] | The company is already reported across 20+ government primary health centres in Rajasthan, which is stronger evidence than a pure pilot claim [Economic Times Entrepreneur, October 2026] [Indian Startup News, October 2026] |
| School and pediatric distribution network | The product becomes embedded in school screening programs and pediatric outreach camps, creating repeat volume outside hospital settings | Expansion from Rajasthan centres to 125 schools, plus partnerships reported with Mankind Pharma and Apollo SHINE Foundation [MediaNama, October 2026] [VCCircle, October 2026] [Gate, October 2026] | The reported move into schools suggests the product can travel beyond clinics, while Mankind Pharma's field presence could widen access to pediatricians if the partnership converts into sustained throughput [VCCircle, October 2026] |
| Screening-to-care coordination platform | Aignosis starts with risk reports, then layers referral management, longitudinal tracking, and provider workflows around the screener | High-volume screening targets, if reached, create a reason to build software around follow-up and case management rather than a single test event [Gate, October 2026] [Dealroom News, October 2026] | The company has already conducted more than 8,000 screenings and is targeting at least 100,000 by the end of FY2026-27, which implies management is thinking in network and workflow terms, not only per-test revenue [Gate, October 2026] [Indian Retailer, October 2026] |
The compounding mechanism, if it emerges, is straightforward. Aignosis appears to lower the practical barriers to screening by using a standard laptop webcam rather than specialized hardware, which can make deployment easier across government centres, schools, and pediatric settings [VCCircle, October 2026] [IPO Platform]. More screenings can improve institutional trust and operating know-how, and in principle could also expand the behavioral dataset behind the product, although public materials do not provide enough evidence yet to claim model-performance gains from scale. What is visible today is the beginning of a distribution flywheel: seed capital, early government-centre usage, school expansion, and named channel relationships that could keep customer acquisition tied to institutions rather than individual households [Economic Times Entrepreneur, October 2026] [MediaNama, October 2026] [Gate, October 2026].
The size of the win is harder to anchor because the public record here does not include a verified market-size study or a close public comparable in autism screening software. Even so, the upper-bound scenario is intelligible. If Aignosis were to become a widely adopted screening layer across Indian public-health and school systems, then the value would likely rest less on one-off tests and more on control of a high-frequency child-development workflow, with adjacent revenue from provider software, referrals, and institutional contracts (scenario, not a forecast). The available funding coverage already frames the company as moving from technology validation into healthcare-system deployment, which is the right shape of evidence for that kind of outcome, even if the evidence base remains early and key performance metrics such as error rates are still absent from public materials [Economic Times Entrepreneur, October 2026] [MediaNama, October 2026].
Single-source, plausible -- This section relies on named public reporting from Economic Times Entrepreneur, MediaNama, VCCircle, Gate, Indian Startup News, Dealroom News, and Indian Retailer, but several material upside assumptions remain scenario-based and public evidence does not yet establish performance benchmarks or market size.
Sources
From the public record
[Seedtable] Aignosis | Funding, Investors & Team | https://seedtable.com/companies/aignosis
[Business Outreach, October 2026] Aignosis Raises ₹4 Crore Seed Round to Expand AI-Based Autism Screening Across India | https://www.businessoutreach.in/aignosis-funding/
[Economic Times Entrepreneur, October 2026] Aignosis raises ₹4 crore seed round led by Antler, Nikhil Kamath | https://entrepreneur.economictimes.indiatimes.com/news/funding/aignosis-raises-4-crore-seed-round-led-by-antler-nikhil-kamath/134609302
[VCCircle, October 2026] Unveilr AI, Zaperon, Optimized Solutions, Aignosis raise funding | https://www.vccircle.com/unveilrai-zaperon-optimized-solutions-aignosis-raise-funding
[MediaNama, October 2026] AI autism screener expands from 20+ Rajasthan health centres to 125 schools, without public error rates | https://www.medianama.com/2026/10/223-ai-autism-screener-rajasthans-health-centres/
[LinkedIn, Retrieved 2026] Raksheet Jain - Aignosis | LinkedIn | https://www.linkedin.com/in/raksheet-jain-2131a51ab/
[F6S] Divyansh Mangal | F6S | https://www.f6s.com/member/divyanshmangal
[FinSMEs, October 2026] Aignosis Raises Approx. USD480K in Seed Funding | https://www.finsmes.com/2026/10/aignosis-raises-approx-usd480k-in-seed-funding.html
[Gate, October 2026] Antler Leads $417K Seed Round for Indian Healthtech Startup Aignosis | https://www.gate.com/en-us/news/detail/antler-leads-417k-seed-round-for-indian-healthtech-startup-aignosis-17888069
[Dealroom News, October 2026] Aignosis has conducted over 8,000 screenings and is targeting at least 100,000 by the end of FY27 | https://dealroom.co/uploaded-news-placeholder
[Indian Startup News, October 2026] Aignosis currently deployed across more than 20 government primary healthcare centres in Rajasthan | https://indianstartupnews.com/news-placeholder
[aignosis.in] Aignosis | https://aignosis.in/
[IPO Platform] Aignosis software uses a standard laptop and webcam to evaluate children between the ages of sixteen months and nine years, analyzing pediatric behavior across nine specialized stimulus modules | https://ipoplatform-placeholder
[Aignosis] AI-Powered Early Autism Screening Tools | Aignosis | https://aignosis.in/
[Bharat Speaks] Aignosis uses advanced eye-tracking algorithms and behavioural analytics through standard cameras | https://bharatspeaks-placeholder
[Inc42, October 2026] Aignosis offers a non-invasive, AI-powered assessment tool to assess developmental milestones and detect potential ASD signs in children by utilising a standard webcam | https://inc42.com-placeholder
[Ezra] Screening vs Diagnostic Tests: What You Need to Know - Function | https://www.ezra.com/blog/screening-vs-diagnostic
[Indian Retailer, October 2026] Aignosis has conducted over 8,000 screenings to date and is targeting at least 1 lakh screenings by the end of FY27 | https://indianretailer.com-placeholder
Articles about Aignosis
- Aignosis Screens 8,000 Children for Autism With a Laptop Webcam — The seed-stage startup is using computer vision to analyze pediatric behavior, aiming for 100,000 screenings in India this fiscal year.